Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Meningococcal infection is a major cause of morbidity and mortality worldwide. Infection with Neisseria meningitidis is most common in young children, teenagers and people with certain medical conditions. Effective polysaccharide and glycoconjugate vaccines for serogroups A, C, W135 and Y have been developed. A similar capsular polysaccharide approach for serogroup B (MenB) has by most been judged as unsuitable, hence, no broad coverage vaccine has been licensed to date. The novel vaccine Bexsero (previously 4CMenB) has been developed and proven safe and immunogenic in clinical trials. AREAS COVERED: The authors outline the constituents of Bexsero and immunogenicity and safety data from preclinical and clinical trials published in peer-reviewed literature, meeting proceedings and publicly-available clinical trial websites from 2000 to 2010. EXPERT OPINION: Bexsero is well tolerated with a proven safety profile, and has demonstrated a robust immune response across different age groups against a range of diverse MenB strains. These data suggest that Bexsero has the ability to provide protection in infants, who are at the greatest risk of developing meningococcal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
Stephens, D. S., Greenwood, B., & Brandtzaeg, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61016-2 · Cited by 978 · cited 12×
“Serogroup A has historically been most prevalent in this region, although recently, serogroups W135 and X have emerged as important disease-causing serogroups [2,5].”
BackgroundInfluentialImpact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/527401 · Cited by 442
Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger
Boisier, P., Nicolas, P., Djibo, S., Taha, M.-K., Jeanne, I., Mainassara, H. B., Tenebray, B., Kairo, K. K., Giorgini, D., & Chanteau, S. (2007) · Clinical Infectious Diseases · doi:10.1086/511646 · Cited by 237 · cited 2×
“Of these, six serogroups A, B, C, Y, W135 [1] and X [2] are responsible for the majority of meningococcal disease globally.”
Background
Cited by
The roles of extracellular vesicles in the immune system
Buzas, E. I. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00763-8 · Cited by 1,220
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Multivalent glycoconjugates as anti-pathogenic agents
Bernardi, A., Jiménez-Barbero, J., Casnati, A., De Castro, C., Darbre, T., Fieschi, F., Finne, J., Funken, H., Jaeger, K.-E., Lahmann, M., et al. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35408j · Cited by 537
Bacterial outer membrane vesicles as a platform for biomedical applications: An update
Li, M., Zhou, H., Yang, C., Wu, Y., Zhou, X., Liu, H., & Wang, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.031 · Cited by 370
Vogel, U., Taha, M.-K., Vazquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 285
Self-citation
Metadata
- Authors
- Bai, X., Findlow, J., & Borrow, R.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-05-26
- Volume
- 11
- Issue
- 7
- Pages
- 969-985
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2143988742
- Cited by
- 106
- References
- 3
- FWCI
- 13.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. https://app.cochat.ai/papers/10.1517/14712598.2011.585965
- The paper
- Bai, X., Findlow, J., & Borrow, R. (2011). Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2011.585965
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.